IONS
Income statement / Annual
Last year (2024), Ionis Pharmaceuticals, Inc.'s total revenue was $705.14 M,
a decrease of 10.48% from the previous year.
In 2024, Ionis Pharmaceuticals, Inc.'s net income was -$453.90 M.
See Ionis Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$705.14 M |
$787.65 M |
$587.00 M |
$810.00 M |
$729.00 M |
$1.12 B |
$599.67 M |
$507.67 M |
$346.62 M |
$283.70 M |
| Cost of Revenue |
$11.22 M
|
$9.13 M
|
$14.00 M
|
$11.00 M
|
$12.00 M
|
$4.00 M
|
$1.82 M
|
$374.64 M
|
$344.32 M
|
$322.29 M
|
| Gross Profit |
$693.92 M
|
$778.51 M
|
$573.00 M
|
$799.00 M
|
$717.00 M
|
$1.12 B
|
$597.85 M
|
$133.02 M
|
$2.30 M
|
-$38.59 M
|
| Gross Profit Ratio |
0.98
|
0.99
|
0.98
|
0.99
|
0.98
|
1
|
1
|
0.26
|
0.01
|
-0.14
|
| Research and Development Expenses |
$901.53 M
|
$899.63 M
|
$833.00 M
|
$643.00 M
|
$535.00 M
|
$466.00 M
|
$414.60 M
|
$374.64 M
|
$344.32 M
|
$322.29 M
|
| General & Administrative Expenses |
$267.50 M
|
$232.60 M
|
$150.30 M
|
$170.90 M
|
$354.00 M
|
$287.00 M
|
$244.62 M
|
$108.49 M
|
$48.62 M
|
$37.17 M
|
| Selling & Marketing Expenses |
-$26,000.00
|
$0.00
|
$700,000.00
|
$15.10 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$267.47 M
|
$232.60 M
|
$151.00 M
|
$186.00 M
|
$354.00 M
|
$287.00 M
|
$244.62 M
|
$108.49 M
|
$48.62 M
|
$37.17 M
|
| Other Expenses |
$0.00
|
$0.00
|
$3.00 M
|
$9.00 M
|
$2.00 M
|
-$686,000.00
|
-$182,000.00
|
-$3.55 M
|
$18.42 M
|
$40.93 M
|
| Operating Expenses |
$1.17 B
|
$1.13 B
|
$984.00 M
|
$829.00 M
|
$889.00 M
|
$753.00 M
|
$659.23 M
|
$483.13 M
|
$392.94 M
|
$359.47 M
|
| Cost And Expenses |
$1.18 B
|
$1.14 B
|
$998.00 M
|
$840.00 M
|
$901.00 M
|
$757.00 M
|
$661.05 M
|
$483.13 M
|
$392.94 M
|
$359.47 M
|
| Interest Income |
-$6.10 M
|
$0.00
|
$25.33 M
|
$10.04 M
|
$30.56 M
|
$52.21 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$84.36 M
|
$0.00
|
$8.12 M
|
$4.30 M
|
$44.99 M
|
$49.00 M
|
$44.79 M
|
$44.75 M
|
$38.80 M
|
$36.73 M
|
| Depreciation & Amortization |
$0.00
|
$22.50 M
|
$22.11 M
|
$19.56 M
|
$17.16 M
|
$15.99 M
|
$12.53 M
|
$8.35 M
|
$9.03 M
|
$10.24 M
|
| EBITDA |
-$475.08 M |
-$230.01 M |
-$227.76 M |
-$239,000.00 |
-$107.88 M |
$411.53 M |
-$18.84 M |
$39.80 M |
-$8.83 M |
-$40.94 M |
| EBITDA Ratio |
-0.67
|
-0.29
|
-0.96
|
-0.03
|
-0.24
|
0.33
|
-0.1
|
0.04
|
-0.13
|
-0.2
|
| Operating Income Ratio |
-0.67
|
-0.45
|
-0.7
|
-0.04
|
-0.24
|
0.33
|
-0.1
|
0.05
|
-0.13
|
-0.27
|
| Total Other Income/Expenses Net |
$15.01 M
|
$19.77 M
|
$152.21 M
|
$1.04 M
|
$37.53 M
|
-$27.12 M
|
-$14.78 M
|
-$47.81 M
|
-$37.31 M
|
-$12.14 M
|
| Income Before Tax |
-$460.07 M
|
-$333.97 M
|
-$258.00 M
|
-$30.00 M
|
-$170.00 M
|
$347.00 M
|
-$76.16 M
|
-$23.28 M
|
-$83.62 M
|
-$87.91 M
|
| Income Before Tax Ratio |
-0.65
|
-0.42
|
-0.44
|
-0.04
|
-0.23
|
0.31
|
-0.13
|
-0.05
|
-0.24
|
-0.31
|
| Income Tax Expense |
-$6.17 M
|
$32.32 M
|
$12.00 M
|
-$1.00 M
|
$317.00 M
|
$44.00 M
|
-$291.14 M
|
-$5.98 M
|
$2.93 M
|
$372,000.00
|
| Net Income |
-$453.90 M
|
-$366.29 M
|
-$270.00 M
|
-$29.00 M
|
-$487.00 M
|
$294.00 M
|
$273.74 M
|
-$5.97 M
|
-$86.56 M
|
-$88.28 M
|
| Net Income Ratio |
-0.64
|
-0.47
|
-0.46
|
-0.04
|
-0.67
|
0.26
|
0.46
|
-0.01
|
-0.25
|
-0.31
|
| EPS |
-3.04 |
-2.56 |
-1.9 |
-0.21 |
-3.49 |
2.1 |
2.07 |
-0.0481 |
-0.72 |
-0.74 |
| EPS Diluted |
-3.04 |
-2.56 |
-1.9 |
-0.21 |
-3.49 |
2.06 |
2.04 |
-0.0473 |
-0.72 |
-0.74 |
| Weighted Average Shares Out |
$149.51 M
|
$143.00 M
|
$141.85 M
|
$141.02 M
|
$139.61 M
|
$140.00 M
|
$132.32 M
|
$124.02 M
|
$120.80 M
|
$119.29 M
|
| Weighted Average Shares Out Diluted |
$149.51 M
|
$143.19 M
|
$141.85 M
|
$141.02 M
|
$139.61 M
|
$142.87 M
|
$134.06 M
|
$126.10 M
|
$120.93 M
|
$119.72 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
